ESG Report 2025

8.2.1 Product Footprint and Business Progress The Group's business covers finished products, bulk medicine and intermediate products, with a pipeline spanning endocrine, metabolic, autoimmune, ophthalmic and anti-infective therapeutic areas. Intermediate Products and Bulk Medicine Finished Products Antibacterials Antidiabetic drugs Antiallergic drugs Antiviral drugs Cold and cough remedies Ophthalmic drugs Topical dermatologicals Cardiovascular and cerebrovvascular drugs Nervous system drugs Health & Wellness Products, etc. Livestock products Poultry products Pet products Aquatic products 6-aminopenicillanic acid (6-APA) T-Octylammonium Clavulanate Penicillin G Potassium First Crystal Intermediate products Bulk medicine Semi-synthetic penicillins Cephalosporins β-lactamase inhibitors and combinations Carbapenems Human Pharmaceuticals Animal Healthcare 58 In the domestic market, the Group is principally engaged in the R&D, production and sales of bulk medicine and intermediate products, finished products, veterinary drugs, pharmaceutical capsules and medical devices, and is one of China's leading integrated modern pharmaceutical enterprises. The Group has a well-established business development team and an extensive business network throughout the country. Domestic Market Broad Market 140,000 OTC Market 170,000 36,000 Medical Market 200 customers Intermediate products & bulk medicine serving 400 customers Animal healthcare serving 273 Number of products available for sale in China Number of terminals covered by finished products The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report